scholarly journals 18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1353
Author(s):  
Romain-David Seban ◽  
Anne Donnadieu ◽  
Gabrielle Journo ◽  
Francois-Clement Bidard ◽  
Capucine Richard ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Solid Tumors ◽  
Fdg Pet ◽  
Metabolic Response ◽  
European Medicines Agency ◽  
Endometrioid Adenocarcinoma ◽  
Pelvic Magnetic Resonance Imaging ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced endometrial cancer. We report the case of a 64-year-old woman, experiencing vaginal recurrence with microsatellite instability high/hypermutated of a FIGO stage IA grade 2 endometrial endometrioid adenocarcinoma. She received preoperative chemotherapy with four cycles of carboplatin plus paclitaxel, with stable disease on pelvic magnetic resonance imaging (MRI) and fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT). Dostarlimab (500 mg intravenously every 3 weeks) was then introduced. The subsequent evaluation after three perfusions demonstrated a complete metabolic response on 18F-FDG PET/CT according to immunotherapy-modified PET response criteria in solid tumors (imPERCIST) criteria, then confirmed by MRI according to immune response evaluation criteria in solid tumors (iRECIST). This clinical description suggests that 18F-FDG PET/CT might take place among available tools for guiding the preoperative management for recurrent endometrial cancer patients receiving dostarlimab immunotherapy that should be further explored through clinical trials.

A systematic review about the role of preoperative 18F-FDG PET/CT for prognosis and risk stratification in patients with endometrial cancer

2021 ◽  
Author(s):  
Edel Noriega-Álvarez ◽  
Ana M. García Vicente ◽  
Germán A. Jiménez Londoño ◽  
Wilson R. Martínez Bravo ◽  
Beatriz González García ◽  
...  
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Risk Stratification ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Prognostic value of preoperative metabolic tumor volume measured by 18F-FDG PET/CT and MRI in patients with endometrial cancer

2013 ◽  
Vol 130 (3) ◽  
pp. 446-451 ◽  
Author(s):  
Hyun Hoon Chung ◽  
Inki Lee ◽  
Hee Seung Kim ◽  
Jae Weon Kim ◽  
Noh-Hyun Park ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Fdg Pet ◽  
Prognostic Value ◽  
Tumor Volume ◽  
Metabolic Tumor Volume ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Ct And Mri

Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization

2019 ◽  
Vol 58 (03) ◽  
pp. 242-248 ◽  
Author(s):  
Amir Sabet ◽  
Martin Ries ◽  
Yamen Al-Khalaf ◽  
Carsten Meyer ◽  
Christian Rudlowski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Response Assessment ◽  
Tumor Burden ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

Abstract Aim To evaluate the feasibility of early metabolic response assessment with 18F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres. Methods 25 patients (mean age 58y, range 40–74) with advanced stage liver metastases of breast cancer were treated with 1.9 ± 0.4 GBq of 90Y-microspheres in the salvage setting and underwent 18F-FDG PET/CT at baseline and 4 weeks post-radioembolization. 14 patients (56 %) had an excessive hepatic tumor burden (> 50 % of total liver volume), 21 patients (84 %) had extrahepatic disease. Liver lesions with the highest SUVmax were selected as target lesions and a cut-off was set at 50 % reduction to separate responders from non-responders. The predictive impact of metabolic response on overall survival (OS) was investigated along with other prognostic factors. Results The median OS in this highly advanced metastatic cohort was 7 months (95 % CI, 5–9). All patients had a reduction in SUVmax (mean ΔSUVmax: –49 ± 26 %) at 4 weeks post-treatment. Patients with > 50 % SUVmax reduction survived longer (median OS 13 mo, 95 % CI 8–18) than the remaining patients (median OS 4 mo, 95 % CI 2–6; p = 0.001). From all investigated baseline factors including age, performance status, and presence of extra-hepatic disease, only the hepatic tumor burden had a significant impact on OS (p = 0.02). Conclusions This is the first preliminary evidence in breast cancer that early post-radioembolization molecular response assessment of treated liver metastases – as early as 4 weeks posttreatment – may predict survival. If confirmed by larger series, FDG PET/CT could be considered for early response-adapted treatment modifications.

Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies

2021 ◽  
Vol 46 (1) ◽  
pp. 52-54
Author(s):  
Romain-David Seban ◽  
Laurence Bozec ◽  
Camila Nascimento-Leite ◽  
Laurence Champion
Keyword(s):  
Targeted Therapies ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Struma Ovarii ◽  
Malignant Struma Ovarii ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Early response evaluation using 18F-FDG-PET/CT does not influence management of patients with metastatic gastrointestinal stromal tumors (GIST) treated with palliative intent

2021 ◽  
Vol 60 (06) ◽  
pp. 411-416
Author(s):  
Sheima Farag ◽  
Nikki S. IJzerman ◽  
Matthijs P.M. Houdijk ◽  
An K.L. Reyners ◽  
Anne IJ Arens ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Metabolic Response ◽  
Early Response ◽  
Ct Scans ◽  
Palliative Intent ◽  
Metastatic Gist ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
The Impact

Abstract Aim The aim of this study was to investigate the impact of 18F-FDG-PET/CT on treatment decision making in metastatic gastrointestinal stromal tumor (GIST) patients. Methods This study retrospectively evaluated 18F-FDG-PET/CT scans to monitor response of metastatic GIST patients treated with palliative intent. Data from the Dutch GIST Registry was used. Early scans (<10 weeks after start of treatment) and late scans (>10 weeks after start of treatment) were scored on the impact in change of treatment. Results Sixty-one PET/CT scans were performed for treatment evaluation in 39 patients with metastatic GIST of which 36 were early scans and 25 were late scans. Early PET/CT scans led to a change in management in 5.6% of patients and late PET/CT scans led to a change in management in 56% of patients. Change in management was more often seen after scans with lack of metabolic response (48% vs. 11% in scans with metabolic response, p=0.002). Neither metabolic response nor change in treatment were more often seen in patients with KIT mutations compared to patients with non-KIT mutations (metabolic response 65% KIT vs. 46% non-KIT, p=0.33, and change in management 28% KIT vs. 21% non-KIT, p=0.74). Conclusion 18F-FDG-PET/CT is not recommended for early response evaluation in an unselected patient population with metastatic GIST, since it does not influence treatment decisions. 18F-FDG-PET/CT, however, can be useful for late response assessment, especially in case of indeterminate CT results.

18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: The early metabolic response is the answer

2013 ◽  
Vol 49 (16) ◽  
pp. 3573-3574
Author(s):  
Salome Sanz-Viedma ◽  
Alfonso Sanchez-Muñoz ◽  
Victoria Scholz-Gutierrez ◽  
Jose Manuel Jimenez-Hoyuela ◽  
Abass Alavi ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Pathologic Complete Response ◽  
Complete Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

scholarly journals OC-0562: Application of low dose 18F-FDG PET/CT for frequent metabolic response monitoring ñ a logistical challenge

2015 ◽  
Vol 115 ◽  
pp. S274-S275
Author(s):  
N.M. Bruin ◽  
J.B. Kamer van de ◽  
J.L. Knegjens ◽  
S.L. Takken ◽  
J.J. Sonke ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Low Dose ◽  
Metabolic Response ◽  
Response Monitoring ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document